Caballero, AC, Escriba-Garcia, L, Alvarez-Fernandez, C, Briones, J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7.300(Q1/3D).

Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).

Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).

Dreyling, M, Andre, M, Gokbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Ribera, JM, Zweegman, S, Aurer, I, Bodor, C, Burkhardt, B, Buske, C, Caballero, MD, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Gronbaek, K, Goldschmidt, H, Kersten, MJ, Kiesewetter, B, Landman-Parker, J, Le Gouill, S, Lenz, G, Leppa, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trumper, LH, Salles, G. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere. 2022; 6(6)DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6.600(Q1/3D).